Lineage Cell Therapeutics (LCTX) Change in Acquisitions & Divestments (2023 - 2026)

Lineage Cell Therapeutics' Change in Acquisitions & Divestments history runs 4 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 198.25% year-over-year to $6.0 million in Q1 2026; TTM through Mar 2026 was $6.0 million, a 195.59% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 11011.11% from the prior year.
• Change in Acquisitions & Divestments grew to $6.0 million in Q1 2026 per LCTX's latest filing, from $2.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $24.3 million in Q2 2023 and bottomed at -$4.0 million in Q4 2024.
• The 4-year median for Change in Acquisitions & Divestments is $5.8 million (2023), against an average of $7.9 million.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 140.5% in 2024 and surged 198.25% in 2026, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $9.8 million in 2023, then tumbled by 140.5% to -$4.0 million in 2024, then soared by 150.23% to $2.0 million in 2025, then jumped by 198.25% to $6.0 million in 2026.
• Per Business Quant, the three latest LCTX Change in Acquisitions & Divestments figures stand at $6.0 million (Q1 2026), $2.0 million (Q1 2025), and -$4.0 million (Q4 2024).